Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PHI-101

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pharos iBT

Drug class:

FLT3 inhibitor, Chk2 inhibitor

Related drugs:

‹

›

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2
FLT3 wild-type	Acute Myelogenous Leukemia	FLT3 wild-type	Acute Myelogenous Leukemia	PHI-101 Sensitive: C3 – Early Trials PHI-101 Sensitive : C3	PHI-101 Sensitive: C3 – Early Trials PHI-101 Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: C3 – Early Trials PHI-101 Sensitive : C3	PHI-101 Sensitive: C3 – Early Trials PHI-101 Sensitive : C3
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3-ITD mutation + FLT3 F691L	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 F691L	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3-ITD mutation + FLT3 D835Y	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 D835Y	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3 D835A	Acute Myelogenous Leukemia	FLT3 D835A	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3 840GS	Acute Myelogenous Leukemia	FLT3 840GS	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3 N676D	Acute Myelogenous Leukemia	FLT3 N676D	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D
FLT3 A627T	Acute Myelogenous Leukemia	FLT3 A627T	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D